- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Patent holdings for IPC class C07D 261/20
Total number of patents in this class: 370
10-year publication summary
|
21
|
31
|
24
|
18
|
19
|
21
|
18
|
20
|
13
|
19
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4880 |
17 |
| President and Fellows of Harvard College | 5986 |
12 |
| Purdue Pharma L.P. | 501 |
11 |
| Theravance Biopharma R&D IP, LLC | 456 |
10 |
| BioCryst Pharmaceuticals, Inc. | 174 |
9 |
| Abbvie Inc. | 1800 |
7 |
| University of Georgia Research Foundation, Inc. | 1030 |
7 |
| Enanta Pharmaceuticals, Inc. | 429 |
6 |
| Calico Life Sciences LLC | 96 |
6 |
| Abiogen Pharma S.p.A. | 155 |
5 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 829 |
5 |
| SynAffix B.V. | 109 |
5 |
| Sumitomo Pharma Co., Ltd. | 605 |
5 |
| Merck Sharp & Dohme LLC | 3751 |
5 |
| F. Hoffmann-La Roche AG | 7947 |
4 |
| BASF SE | 20940 |
4 |
| CHDI Foundation, Inc. | 106 |
4 |
| Sunshine Lake Pharma Co., Ltd. | 597 |
4 |
| Toyama Chemical Co., Ltd. | 102 |
4 |
| Ctxt Pty Ltd | 52 |
4 |
| Other owners | 236 |